DexCom, Inc. (DXCM)

DXCM Income Statement

Revenue, expenses, and profitability analysis

DXCM Quarterly Income Statement (USD)

Quarterly Report	TTM	03/31/2026	12/31/2025	09/30/2025	06/30/2025	03/31/2025	12/31/2024	09/30/2024	06/30/2024
Gross Profit	2.979B	750.300M	792.700M	747.400M	688.800M	589.000M	655.800M	593.800M	626.700M
Revenue	4.818B	1.192B	1.260B	1.209B	1.157B	1.036B	1.113B	994.200M	1.004B
Cost of Goods Sold	1.839B	441.600M	466.900M	461.900M	468.300M	447.000M	457.700M	400.400M	377.600M
Gross Profit Margin	62.9%	62.9%	62.9%	61.8%	59.5%	56.9%	58.9%	59.7%	62.4%
Total Operating Expenses	1.946B	495.000M	469.700M	504.900M	476.200M	455.300M	466.900M	441.800M	468.700M
Research & Development	599.200M	145.300M	148.200M	157.500M	148.200M	145.200M	139.500M	135.400M	136.000M
Selling, General & Administrative	1.331B	349.700M	321.500M	331.400M	328.000M	310.100M	327.400M	306.400M	332.700M
Operating Income (EBIT)	1.033B	255.300M	323.000M	242.500M	212.600M	133.700M	188.900M	152.000M	158.000M
Operating Margin	21.4%	21.4%	25.6%	20.1%	18.4%	12.9%	17.0%	15.3%	15.7%
Income Before Tax (EBT)	1.204B	269.500M	340.700M	352.300M	241.100M	154.300M	211.300M	177.400M	187.800M
Interest Income	84.200M	—	23.500M	32.700M	28.000M	28.500M	29.700M	32.000M	36.200M
Interest Expense	13.600M	—	4.200M	4.700M	4.700M	4.700M	4.900M	4.700M	4.800M
Other Income/Expense	170.200M	14.200M	17.700M	109.800M	28.500M	20.600M	22.400M	25.400M	29.800M
Net Income	930.400M	199.500M	267.300M	283.800M	179.800M	105.400M	151.700M	134.600M	143.500M
Income Tax Expense	273.200M	70.000M	73.400M	68.500M	61.300M	48.900M	59.600M	42.800M	44.300M
Net Profit Margin	16.7%	16.7%	21.2%	23.5%	15.5%	10.2%	13.6%	13.5%	14.3%
EBITDA	1.292B	322.400M	388.200M	306.100M	275.600M	193.700M	274.000M	237.400M	244.700M
EBITDA Margin	27.0%	27.0%	30.8%	25.3%	23.8%	18.7%	24.6%	23.9%	24.4%
Depreciation & Amortization	258.900M	67.100M	65.200M	63.600M	63.000M	60.000M	57.800M	55.300M	52.100M
EPS Basic	2.40	0.52	0.69	0.73	0.46	0.27	0.39	0.35	0.36
EPS Diluted	2.34	0.51	0.68	0.70	0.45	0.27	0.38	0.34	0.35
Shares Outstanding	385.100M	385.100M	386.700M	391.100M	392.100M	391.100M	399.330M	394.200M	399.200M
Diluted Shares Outstanding	393.600M	393.600M	398.900M	407.400M	408.200M	407.500M	406.700M	410.200M	416.800M

DXCM Annual Income Statement (USD)

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Gross Profit	2.798B	2.438B	2.289B	1.883B	1.681B	1.280B	931.500M	663.900M
Revenue	4.662B	4.033B	3.622B	2.910B	2.449B	1.927B	1.476B	1.032B
Cost of Goods Sold	1.864B	1.595B	1.333B	1.027B	768.000M	646.600M	544.500M	367.700M
Gross Profit Margin	60.0%	60.5%	63.2%	64.7%	68.6%	66.4%	63.1%	64.4%
Total Operating Expenses	1.886B	1.838B	1.691B	1.492B	1.415B	980.600M	789.200M	850.200M
Research & Development	594.900M	552.400M	505.800M	484.200M	604.200M	359.900M	273.500M	417.400M
Selling, General & Administrative	1.291B	1.286B	1.185B	1.008B	810.500M	620.700M	515.700M	432.800M
Operating Income (EBIT)	911.800M	600.000M	597.700M	391.200M	265.800M	299.500M	142.300M	-186.300M
Operating Margin	19.6%	14.9%	16.5%	13.4%	10.9%	15.5%	9.6%	-18.1%
Income Before Tax (EBT)	1.088B	709.000M	710.400M	390.800M	256.800M	225.000M	104.200M	-126.500M
Interest Income	112.700M	134.200M	135.000M	23.800M	1.700M	16.100M	26.400M	2.400M
Interest Expense	18.300M	19.000M	20.300M	18.600M	18.800M	84.700M	60.300M	22.700M
Other Income/Expense	176.600M	109.000M	112.700M	-400K	-9.000M	-74.500M	-38.100M	59.800M
Net Income	836.300M	576.200M	541.500M	341.200M	216.900M	493.600M	101.100M	-127.100M
Income Tax Expense	252.100M	132.800M	168.900M	49.600M	39.900M	-268.600M	3.100M	600K
Net Profit Margin	17.9%	14.3%	14.9%	11.7%	8.9%	25.6%	6.8%	-12.3%
EBITDA	1.164B	945.700M	916.700M	565.300M	377.500M	376.800M	213.200M	-74.700M
EBITDA Margin	25.0%	23.4%	25.3%	19.4%	15.4%	19.6%	14.4%	-7.2%
Depreciation & Amortization	251.800M	217.700M	186.000M	155.900M	101.900M	67.100M	48.700M	29.100M
EPS Basic	2.14	1.46	1.44	0.88	0.56	1.31	0.28	-0.36
EPS Diluted	2.09	1.42	1.30	0.80	0.51	1.27	0.27	-0.36
Shares Outstanding	390.200M	404.625M	386.000M	389.400M	386.900M	377.600M	364.400M	352.800M
Diluted Shares Outstanding	405.500M	412.700M	425.500M	427.500M	428.800M	390.000M	369.200M	352.800M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About DexCom, Inc.

DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.

San Diego, CA

10,200 employees

www.dexcom.com

Healthcare / Medical - Devices

Sector: Healthcare
Industry: Medical - Devices
CEO: Jacob Steven Leach

View full financials